![]() |
市場調查報告書
商品編碼
1500392
下一代 IVD 市場:按產品、應用和最終用戶分類 - 2024-2030 年全球預測Next-Generation IVD Market by Product (Consumables, Instruments, Software), Application (Autoimmune Diseases, Cardiology, Diabetes), End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
下一代IVD市場規模預計2023年為625.2億美元,2024年達到656億美元,預計2030年將達到893.9億美元,複合年成長率為5.23%。
下一代體外診斷(IVD)是指在人類體外受控環境(例如試管或實驗室)中進行的先進診斷測試。這些創新診斷涵蓋各種技術、工具和方法,旨在更準確、快速、有效率地檢測和監測疾病、病症和感染疾病。 「下一代」一詞強調這些診斷結合了分子診斷、照護現場技術和數位健康技術的進步,比傳統方法得到了顯著增強。同時,感染疾病和慢性病的全球流行正在推動下一代體外診斷的發展。然而,下一代體外診斷藥物的監管情況複雜且嚴格,核准往往需要時間。此外,保險報銷政策並不總是有利於新的診斷技術,從而影響了市場滲透率。此外,次世代定序、聚合酵素鏈鎖反應(PCR) 和生物晶片等技術創新顯著提高了診斷測試的準確性、速度和可靠性,推動了對下一代 IVD 解決方案的需求。
主要市場統計 | |
---|---|
基準年[2023] | 625.2億美元 |
預測年份 [2024] | 656億美元 |
預測年份 [2030] | 893.9億美元 |
複合年成長率(%) | 5.23% |
區域洞察
在美洲,美國和加拿大在研究和開發方面處於領先地位,這得益於對研究的大量投資和強大的專利框架。消費者對早期疾病檢測和個人化治療的好處的高度認知正在推動該地區對先進體外診斷 (IVD) 解決方案的需求。最近政府採取的旨在將下一代診斷納入國家衛生計畫的舉措進一步推動了對下一代體外診斷的需求。 EMEA(歐洲、中東和非洲)地區的特點是強勁成長和創新技術進步。該市場是由慢性病的增加以及基因組學和蛋白質組學在診斷中的整合所推動的。歐洲、中東和非洲地區的法規環境也不斷調整,旨在促進創新,同時確保病患安全,在市場動態中發揮關鍵作用。此外,亞太地區向下一代體外診斷的轉變主要是由醫療保健領域對快速、準確和個人化診斷解決方案不斷成長的需求所推動的。該地區人口眾多且老化,以及對疾病早期檢測意識的增強是推動市場發展的關鍵因素。此外,旨在改善醫療基礎設施和可近性的政府措施和研發投資正在促進先進 IVD 技術的整合。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在下一代 IVD 市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對下一代 IVD 市場中供應商的現狀進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在下一代 IVD 市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[194 Pages Report] The Next-Generation IVD Market size was estimated at USD 62.52 billion in 2023 and expected to reach USD 65.60 billion in 2024, at a CAGR 5.23% to reach USD 89.39 billion by 2030.
Next-Generation In Vitro Diagnostics (IVD) refers to the advanced phase of diagnostics tests conducted outside a human body, in a controlled environment such as a test tube or a laboratory. These innovative diagnostics encompass various technologies, tools, and methods designed to offer more precise, faster, and more efficient detection and monitoring of diseases, conditions, and infections. The term 'Next-Generation' underscores the significant enhancements these diagnostics represent over traditional methods, incorporating advancements in molecular diagnostics, point-of-care techniques, and digital health technologies. Meanwhile, the growing prevalence of infectious and chronic diseases worldwide is propelling the growth of next-generation IVDs. However, the regulatory landscape for next-generation IVDs can be complex and rigorous, often resulting in longer approval times. Additionally, reimbursement policies may not always favor novel diagnostic technologies, impacting their market penetration. Moreover, continuous innovation in technologies such as next-generation sequencing, polymerase chain reaction (PCR), and biochips are significantly enhancing diagnostic tests' accuracy, speed, and reliability, thus driving the demand for next-generation IVD solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 62.52 billion |
Estimated Year [2024] | USD 65.60 billion |
Forecast Year [2030] | USD 89.39 billion |
CAGR (%) | 5.23% |
Regional Insights
In the Americas, the United States and Canada are at the forefront of next-generation IVD development, spurred by significant investments in research and a strong patent framework. High consumer awareness about the benefits of early disease detection and personalized treatment plans drives the region's demand for advanced IVD solutions. Recent government initiatives focused on incorporating next-generation diagnostics in national health programs further drive the demand for next-generation IVDs. The EMEA region has been characterized by robust growth and transformative technological advancements. The market is driven by the increasing prevalence of chronic diseases and the integration of genomics and proteomics in diagnostics. Regulatory environments across EMEA have also adapted, aiming to foster innovation while ensuring patient safety, thereby playing a pivotal role in market dynamics. Moreover, the shift towards next-generation IVDs in the Asia-Pacific region is primarily fueled by the increasing demand for fast, accurate, and personalized diagnostic solutions across the healthcare sector. The region's large and aging population and the growing awareness about early disease detection are key factors propelling the market forward. Furthermore, government initiatives aimed at improving healthcare infrastructure and accessibility, coupled with investments in research and development, are facilitating the integration of advanced IVD technologies.
Market Insights
The market dynamics represent an ever-changing landscape of the Next-Generation IVD Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Next-Generation IVD Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Next-Generation IVD Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Collaboration: Illumina and Devyser Diagnostics Forge Path in IVD Innovation
Illumina, the pioneer in DNA sequencing and array-based technologies, has entered a strategic agreement with Devyser Diagnostics. By leveraging Illumina's formidable expertise in genomics alongside Devyser Diagnostics' specialized focus on diagnostic testing solutions, this collaboration marks a critical step forward in developing novel IVD offerings. [Published On: 2024-01-08]
Fapon Biotech Advances IVD Landscape and Targets Next-Generation Therapeutics Expansion
Fapon Biotech is strategically expanding its comprehensive solutions, encompassing IVD raw materials and end-use product development services. This initiative is characterized by their significant investments in next-generation therapeutics, specifically in infectious diseases and oncology. [Published On: 2023-09-15]
Waters Corporation Introduces Revolutionary Xevo TQ Absolute IVD Mass Spectrometer
Waters Corporation unveiled the Xevo TQ Absolute IVD Mass Spectrometer, poised to redefine efficiency and sensitivity in clinical diagnostics. This cutting-edge instrument departs from traditional mass spectrometry techniques by offering unparalleled analytical performance and ease of use. The Xevo TQ Absolute IVD stands out for its remarkably compact design, which requires 50% less bench space, alongside an enhanced sensitivity that promises to accelerate lab workflows by doubling the number of tests conducted within the same timeframe. [Published On: 2023-04-04]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Next-Generation IVD Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Next-Generation IVD Market, highlighting leading vendors and their innovative profiles. These include ABL SA Group, Agilent Technologies Inc., Archer by Integrated DNA Technologies, Inc., Becton, Dickinson and Company, Biomerieux SA, BioVendor - Laboratorni medicina A.S., Cerba Research NV, Curetis N.V., Danaher Corporation, F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Fulgent Genetics, Inc., Geneseeq Technology Inc., Genomic Labs Ltd., Illumina, Inc., Invivoscribe, Inc., NGenBio Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pillar Biosciences Inc., QIAGEN GmbH, Sophia Genetics SA, Sysmex Europe SE, Tempus Labs, Inc., Thermo Fisher Scientific Inc., Trivitron Healthcare, and Vela Diagnostics Holding Pte Ltd..
Market Segmentation & Coverage